Drug intelligence / Profile preview

cabazitaxel + carboplatin

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of cabazitaxel (a taxane chemotherapy drug) and carboplatin (a platinum-containing compound). This combination has shown improved clinical efficacy compared to cabazitaxel alone for treating metastatic castration-resistant prostate cancer (mCRPC). Cabazitaxel works by preventing cancer cells from dividing properly, while carboplatin kills cancer cells by damaging their DNA. The combination has demonstrated synergistic effects, particularly in patients who have progressed on cabazitaxel monotherapy.

Targets

DNA

Beyond the preview

Go deeper on cabazitaxel + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cabazitaxel + carboplatin.

Explore the full profile